Center for Cell Death, Injury & Regeneration, Department of Pharmaceutical & Biomedical Sciences, Medical University of South Carolina, Charleston, 29425, USA.
Biochem J. 2010 Nov 1;431(3):411-21. doi: 10.1042/BJ20091741.
NO and cGMP administered at reperfusion after ischaemia prevent injury to hepatocytes mediated by the MPT (mitochondrial permeability transition). To characterize further the mechanism of protection, the ability of hepatic cytosol in combination with cyclic nucleotides to delay onset of the calcium-induced MPT was evaluated in isolated rat liver mitochondria. Liver cytosol plus cGMP or cAMP dose-dependently inhibited the MPT, required ATP hydrolysis for inhibition and did not inhibit mitochondrial calcium uptake. Specific peptide inhibitors for PKA (protein kinase A), but not PKG (protein kinase G), abolished cytosol-induced inhibition of MPT onset. Activity assays showed a cGMP- and cAMP-stimulated protein kinase activity in liver cytosol that was completely inhibited by PKI, a PKA peptide inhibitor. Size-exclusion chromatography of liver cytosol produced a single peak of cGMP/cAMP-stimulated kinase activity with an estimated protein size of 180-220 kDa. This fraction was PKI-sensitive and delayed onset of the MPT. Incubation of active catalytic PKA subunit directly with mitochondria in the absence of cytosol and cyclic nucleotide also delayed MPT onset, and incubation with purified outer membranes led to phosphorylation of a major 31 kDa band. After ischaemia, administration at reperfusion of membrane-permeant cAMPs and cAMP-mobilizing glucagon prevented reperfusion injury to hepatocytes. In conclusion, PKA in liver cytosol activated by cGMP or cAMP acts directly on mitochondria to delay onset of the MPT and protect hepatocytes from cell death after ischaemia/reperfusion.
NO 和 cGMP 在缺血再灌注时给药可防止 MPT(线粒体通透性转换)介导的肝实质细胞损伤。为了进一步阐明保护机制,评估了肝胞质在与环核苷酸组合时延迟钙诱导的 MPT 发作的能力,以分离的大鼠肝线粒体。肝胞质加 cGMP 或 cAMP 呈剂量依赖性抑制 MPT,抑制需要 ATP 水解,不抑制线粒体钙摄取。PKA(蛋白激酶 A)的特异性肽抑制剂,但不是 PKG(蛋白激酶 G),可消除胞质诱导的 MPT 起始抑制。活性测定显示肝胞质中的 cGMP 和 cAMP 刺激的蛋白激酶活性,PKI(PKA 肽抑制剂)完全抑制该活性。肝胞质的排阻层析产生 cGMP/cAMP 刺激的激酶活性的单一峰,估计蛋白质大小为 180-220 kDa。该部分是 PKI 敏感的,可延迟 MPT 的发作。在没有胞质和环核苷酸的情况下,直接将活性催化 PKA 亚基与线粒体孵育也会延迟 MPT 的发作,并且与纯化的外膜孵育会导致主要的 31 kDa 带磷酸化。在缺血后,再灌注时给予膜通透的 cAMPs 和 cAMP 动员的胰高血糖素可防止肝实质细胞再灌注损伤。总之,由 cGMP 或 cAMP 激活的肝胞质中的 PKA 直接作用于线粒体,以延迟 MPT 的发作,并在缺血/再灌注后保护肝实质细胞免于死亡。